DCDanielle Daffre Carvalho

Danielle Daffre Carvalho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danielle Daffre Carvalho has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The transcription factor Relish controls Anaplasma marginale infection in the bovine tick Rhipicephalus microplus

    by J. Capelli-Peixoto, Danielle D. Carvalho, Wendell C. Johnson, Glen A. Scoles, Andrea C. Fogaça, Sirlei Daffre, Massaro W. Ueti


  • Open Access

    Intensidade e Adoção da Inovação no Mercado da Base da Pirâmide: um estudo com produtos eletrodomésticos

    by Vitor Koki da Costa Nogami, Danielle Daffre Carvalho, Geraldo Luciano Toledo, Andres Rodriguez Veloso, Maria Aparecida Gouvêa

    O artigo analisa as características da intensidade e da adoção da inovação no mercado da base da pirâmide. A intensidade da inovação se configura como radical e incremental, enquanto que a adoção da inovação se configura como inicial e tardia. Como recorte empírico foi realizada uma pesquisa do tipo survey. A análise dos dados se fundamenta na estatística não paramétrica. Os resultados apontam que os consumidores da base da pirâmide se caracterizam por adotarem inovações incrementais de forma tardia, conforme aponta a literatura. Ademais, foi possível concluir também que as mulheres possuem maior poder de decisão nas famílias deste segmento.


  • Open Access

    Intensidade e Adoção da Inovação no Mercado da Base da Pirâmide: um estudo com produtos eletrodomésticos

    by Vitor Koki da Costa Nogami, Danielle Daffre Carvalho, Geraldo Luciano Toledo, Andres Rodriguez Veloso, Maria Aparecida Gouvêa

    The paper analyzes the innovation intensity and adoption characteristics at the base of the pyramid market. The innovation intensity is configured as radical and incremental, while the innovation adoption is configured as early and tardy. As an empirical approach it was conducted a study type survey. Data analysis is based on non-parametric statistics. The results indicate that the base of the pyramid consumers is characterized by adopting incremental innovations tardily, as pointed out by the literature. Furthermore, it was also observed that women have greater decision-making power in the families of this segment.


  • Open Access

    Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesianain the control of experimental candidiasis

    by Diego C Rossi, Julian E Muñoz, Danielle D Carvalho, Rodrigo Belmonte, Bluma Faintuch, Primavera Borelli, Antonio Miranda, Carlos P Taborda, Sirlei Daffre

    Background: Antimicrobial peptides are present in animals, plants and microorganisms and play a fundamental role in the innate immune response. Gomesin is a cationic antimicrobial peptide purified from haemocytes of the spider Acanthoscurria gomesiana. It has a broad-spectrum of activity against bacteria, fungi, protozoa and tumour cells. Candida albicans is a commensal yeast that is part of the human microbiota. However, in immunocompromised patients, this fungus may cause skin, mucosal or systemic infections. The typical treatment for this mycosis comprises three major categories of antifungal drugs: polyenes, azoles and echinocandins; however cases of resistance to these drugs are frequently reported. With the emergence of microorganisms that are resistant to conventional antibiotics, the development of alternative treatments for candidiasis is important. In this study, we evaluate the efficacy of gomesin treatment on disseminated and vaginal candidiasis as well as its toxicity and biodistribution. Results: Treatment with gomesin effectively reduced Candida albicans in the kidneys, spleen, liver and vagina of infected mice. The biodistribution of gomesin labelled with technetium-99 m showed that the peptide is captured in the kidneys, spleen and liver. Enhanced production of TNF-α, IFN-γ and IL-6 was detected in infected mice treated with gomesin, suggesting an immunomodulatory activity. Moreover, immunosuppressed and C. albicans-infected mice showed an increase in survival after treatment with gomesin and fluconazole. Systemic administration of gomesin was also not toxic to the mic Conclusions: Gomesin proved to be effective against experimental Candida albicans infection. It can be used as an alternative therapy for candidiasis, either alone or in combination with fluconazole. Gomesin's mechanism is not fully understood, but we hypothesise that the peptide acts through the permeabilisation of the yeast membrane leading to death and/or releasing the yeast antigens that trigger the host immune response against infection. Therefore, data presented in this study reinforces the potential of gomesin as a therapeutic antifungal agent in both humans and animals.